



The Myriad Promise™

At Myriad, we believe every patient should have access to the highest quality genetic testing because we know providers need the best tools available. That's why EndoPredict is backed by the Myriad Promise.

We are committed to making sure test results are accurate, timely, and financially accessible to everyone. Myriad will help you manage the cost of EndoPredict by working with your insurance company to make sure you get the coverage your plan offers.

If you have any questions or concerns about your invoice from Myriad, please call the phone number on the invoice. Myriad will work with you to reach a solution.

To learn more about the Myriad Promise, visit www.MyriadPromise.com.



Myriad  Promise™

Supporting broad access for patients
For more information, visit myriadpromise.com.

www.EndoPredict.com



Myriad Oncology
320 Wakara Way, Salt Lake City, UT 84108
www.Myriad-Oncology.com | 800-469-7423

Myriad, the Myriad logo, EndoPredict, the EndoPredict logo, Myriad Promise, and the Myriad Promise logo are either trademarks or registered trademarks of Myriad Genetics Inc. in the United States and other jurisdictions. Copyright © 2020 Myriad Genetics, Inc. All rights reserved. EPPATBRO/11-20



Helping guide confident treatment decisions

For ER+, HER2- early-stage breast cancer

ER+, estrogen receptor-positive;
HER2-, human epidermal growth
factor receptor 2-negative.



What is EndoPredict®?

After learning you have breast cancer, it can be hard to understand all of your options for testing and treatment. Using your first biopsy, the amount of protein made by different genes was checked. These genes were:

- ◆ Estrogen receptor, or ER
- ◆ Progesterone receptor (pro-JES-tuh-rohn re-SEP-tuhr), or PR
- ◆ Human epidermal growth factor receptor 2, or HER2

Knowing whether your tumor makes these proteins helps your doctor treat your breast cancer. Tumors that make the ER protein but not the HER2 protein are called ER positive (or ER+) and HER2 negative (or HER2-). For ER+ and HER2- tumors, more testing can help determine the best course of treatment.

EndoPredict is a test for patients with ER+, HER2- breast cancer in early stages

EndoPredict calculates the chance that your cancer will return in the 10 years after treatment, offering important information about how aggressive your cancer is. Knowing this information can help you and your doctor make well-informed choices about your treatment.

WHY DOES YOUR DOCTOR TRUST ENDOPREDICT?

- ◆ EndoPredict provides highly accurate test results for confident, long-term decision-making.
- ◆ It uses genetic information and other tumor features to calculate your personal results.
- ◆ Medical guidelines include EndoPredict.
- ◆ EndoPredict accurately identifies more patients who may safely forgo chemotherapy.
- ◆ EndoPredict is offered by Myriad, a company that has been a trusted name in diagnostic testing for over 25 years.



Knowing your risk is important for your treatment

After surgery, you will make treatment choices with the goal of lowering the chance that your cancer will return, or recur, in the future. For patients, like you, who have ER+ breast cancer, endocrine therapy is standard, or routine. It can lower the risk of the cancer returning – also called the risk of recurrence – by almost half. Some patients will receive both endocrine therapy and chemotherapy. Your doctor will weigh several factors to decide if adding chemotherapy would benefit you further.

What do your EndoPredict test results mean?

The EndoPredict report provides details about your specific cancer. It shows the risk of your cancer returning in the 10 years after treatment if you do not have chemotherapy. Your results will clearly note whether you are **low risk** or **high risk**.

- ◆ A **low-risk** result means that if you do not have chemotherapy, the risk of your cancer returning within 10 years is **low**.
- ◆ A **high-risk** result means that if you do not have chemotherapy, the risk of your cancer returning within 10 years is **high**.


Creating a treatment plan that's right for you



For patients who have a **long-term risk of recurrence that is LOW**, adding chemotherapy is unlikely to improve the absolute benefit by much.

For patients who have a **long-term risk of recurrence that is HIGH**, adding chemotherapy may help significantly lower the risk.

SAMPLE ENDOPREDICT TEST RESULTS



The **EPclin risk score** shows your risk of cancer recurrence as either low or high.

This percent is the risk of your cancer returning within 10 years if you do not have chemotherapy.

Making informed treatment choices

Your EndoPredict report has different ways to convey your risk level. Your doctor will explain what your results mean for you. He or she will consider several factors to decide your best treatment, such as:

- ◆ Your EndoPredict results
- ◆ The risks of chemotherapy
- ◆ Other diseases or conditions you may have
- ◆ Your age
- ◆ Your wishes



Getting accurate information that is unique to your specific cancer can help you make the right treatment choice.